Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment
By Kelly Cloonan
Shares of Armata Pharmaceuticals rose after the company got breakthrough therapy designation from the Food and Drug Administration for a potential antibacterial treatment.
The stock gained 10% to $5.92 in premarket trading on Monday. As of Friday's market close, shares were down 14% year to date.
The breakthrough designation expedites the review of medicines that treat serious or life-threatening conditions, and that have shown the potential for substantial improvement over available therapies based on preliminary clinical evidence.
Armata said it got the designation for AP-SA02, its intravenously-administered product candidate for adjunct treatment of complicated bacteremia caused by methicillin-sensitive staphylococcus aureus or methicillin-resistant S. aureus.
Complicated S. aureus bacteremia is a serious bloodstream infection associated with significant relapse rate, morbidity and mortality, the company said.
The company said it plans to work closely with the FDA to efficiently advance the development and review of AP-SA02, with the goal of bringing the potential new treatment option to patients as quickly as possible.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
September 14, 2026 09:02 ET (13:02 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The 10 Best Companies to Invest in Now
10 Top-Performing US Dividend Stocks
United States